Innate Pharma SA Sponsored ADR (IPHA) Stock Price

1.48 ▲ +0.08 (+5.71%)
Open: 1.45 Vol: 67.43K Day's range: 1.45 - 1.49 Apr 29, 16:00 EDT
IEX quote, 15 minutes delayed during trading hours. Login or Signup to see real-time data
Free Stock Screener
Loading chart ...
IPHA Technical Analysis
5 mins 30 mins Hourly Daily Weekly
SELL SELL SELL SELL SELL
  5 mins 30 mins Hourly Daily Weekly
MA5 1.42▲ 1.42▲ 1.42▲ 1.41▲ 1.47▲
MA10 1.41▲ 1.42▲ 1.43▲ 1.49▼ 1.46▲
MA20 1.51▼ 1.54▼ 1.53▼ 1.47▲ 1.61▼
MA50 1.49▼ 1.43▲ 1.41▲ 1.49▼ 1.84▼
MA100 1.43▲ 1.50▼ 1.52▼ 1.63▼ 1.95▼
MA200 1.58▼ 1.63▼ 1.65▼ 1.82▼ 2.35▼
  5 mins 30 mins Hourly Daily Weekly
MACD -0.009▼ -0.018▼ -0.020▼ -0.007▼ -0.001▼
RSI 44.223▼ 47.558▼ 48.423▼ 51.154▲ 44.507▼
STOCH 58.798     36.865     25.876     14.817▼ 41.761    
WILL %R -66.901     -68.027     -73.446     -67.500     -56.944    
CCI 10.143     -17.000     -29.021     -21.899     -45.737    
Latest Filters Detected On IPHA
▲ RSI&VOL $IPHA RSI Cross Up and Volume Set Alert
RSI $IPHA RSI(14) Crossed Above 50 Set Alert
MA $IPHA Price Crossed Above MA(26) Set Alert
MA $IPHA Price Crossed Above MA(7) Set Alert
▲ GAP $IPHA Open Gap Up %3 Set Alert
▲ GAP $IPHA Open Gap Up %2 Set Alert
Innate Pharma SA Sponsored ADR News
Innate Pharma SA: Innate Pharma to Participate in the D. Boral Capital Global Conference
Thursday, April 23, 2026 01:03 AM
Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) ("Innate" or the "Company"), a clinical-stage biotechnology company developing immunotherapies for cancer patients, today announced ...
Innate Pharma to Participate in the D. Boral Capital Global Conference
Wednesday, April 22, 2026 10:00 PM
Innate Pharma S.A. is a global, clinical-stage biotechnology company developing immunotherapies for cancer patients. Leveraging its expertise on antibody-engineering and innovative target ...
Innate Pharma to Present MATISSE Phase 2 Interim Results of IPH5201 in Clinical Trials Plenary Session at AACR 2026
Friday, April 17, 2026 11:59 AM
Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) ("Innate" or the "Company"), today announced that interim results from the MATISSE Phase 2 study evaluating IPH5201 in combination with durvalumab ...
IPHA historical stock data
date open high low close volume
29/04/26 1.45 1.49 1.45 1.48 67,428
28/04/26 1.41 1.43 1.3901 1.40 11,989
27/04/26 1.39 1.40 1.36 1.40 9,926
24/04/26 1.35 1.42 1.35 1.41 26,674
23/04/26 1.44 1.45 1.37 1.37 4,039
22/04/26 1.46 1.47 1.39 1.43 25,444
21/04/26 1.5301 1.56 1.51 1.51 7,893
20/04/26 1.63 1.65 1.57 1.59 13,777
17/04/26 1.6101 1.7079 1.6006 1.66 50,318
16/04/26 1.69 1.69 1.62 1.62 55,522
Quote Details
52wk Low:1.17
52wk High:2.63
Vol:67.43K
Avg Vol(3m):463.7K
1Y Chng:-28.85%
1M Chng:+12.98%
Add to Watch List
More Information
Index US Composite
Market Cap. 131.36M